ARTV
Artiva Biotherapeutics Inc

843
Mkt Cap
$103.82M
Volume
12.00
52W High
$11.55
52W Low
$1.47
PE Ratio
-1.30
ARTV Fundamentals
Price
$4.23
Prev Close
$4.29
Open
$4.33
50D MA
$3.92
Beta
1.40
Avg. Volume
2.53M
EPS (Annual)
-$2.69
P/B
0.80
Rev/Employee
$2,820.22
Loading...
Loading...
News
all
press releases
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the company...
MarketBeat·19d ago
News Placeholder
More News
News Placeholder
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat Ratings...
MarketBeat·1mo ago
News Placeholder
Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average...
MarketBeat·2mo ago
News Placeholder
Fred Aslan Sells 6,375 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 6,375 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Forecasts Strong Price Appreciation for Artiva Biotherapeutics (NASDAQ:ARTV) Stock
HC Wainwright boosted their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat·2mo ago
News Placeholder
Artiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·2mo ago
News Placeholder
Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally
Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.
Stocktwits·3mo ago
<
...
1
>

Latest ARTV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.